Answers are grounded in this paper and cite their sources.
Use of a specific class of overactive bladder medication was not associated with negative changes in brain function among patients with either normal or abnormal function. A genetic risk factor for Alzheimer's disease did not predispose individuals to cognitive decline when taking these drugs. Two of the drugs (oxybutynin and tolterodine) may lead to a higher risk of cognitive decline in comparison to other drugs, and this needs further research.
No takes yet. Share an insight, caveat, or question.
Welk et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: